Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. Ballantyne CM, Banka P, Mendez G, Garcia R, et al. J Am Coll Cardiol 2023;81:1553-1564.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ballantyne CM, Banka P, Mendez G, Garcia R, et al. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol 2023;81:1553-1564.
PMID: 36889610